DACA

• Description :

  DACA (XR 5000) is a blood-brain barrier-penetrating topoisomerase I and II inhibitor. DACA can be used in the research of colorectal cancer, leukemia and lung cancer[1][2][3][4].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Topoisomerase

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/daca.html

• Concentration :

  10mM

• Purity :

  98.0

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(C1=CC=CC2=CC3=CC=CC=C3N=C12)NCCN(C)C

• Molecular Formula :

  C18H19N3O

• Molecular Weight :

  293.36

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Padget K, et al. An investigation into the formation of N- [2- (dimethylamino) ethyl]acridine-4-carboxamide (DACA) and 6-[2- (dimethylamino) ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells. Biochem Pharmacol. 2000;60 (6) :817-821.|[2]Dittrich C, et al. Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. Eur J Cancer. 2003 Feb;39 (3) :330-4. |[3]Caponigro F, et al. Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. Eur J Cancer. 2002 Jan;38 (1) :70-4. |[4]Twelves CJ, et al. Phase I and pharmacokinetic study of DACA (XR5000) : a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee. Br J Cancer. 1999 Aug;80 (11) :1786-91.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Topo I; Topo II

• CAS Number :

  [89459-25-6]